Chao‐Hung Hung

815 total citations
18 papers, 585 citations indexed

About

Chao‐Hung Hung is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Chao‐Hung Hung has authored 18 papers receiving a total of 585 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hepatology, 17 papers in Epidemiology and 1 paper in Surgery. Recurrent topics in Chao‐Hung Hung's work include Hepatitis C virus research (16 papers), Liver Disease Diagnosis and Treatment (16 papers) and Hepatitis B Virus Studies (13 papers). Chao‐Hung Hung is often cited by papers focused on Hepatitis C virus research (16 papers), Liver Disease Diagnosis and Treatment (16 papers) and Hepatitis B Virus Studies (13 papers). Chao‐Hung Hung collaborates with scholars based in Taiwan and United States. Chao‐Hung Hung's co-authors include Tsung‐Hui Hu, Jing‐Houng Wang, Sheng‐Nan Lu, Chien‐Hung Chen, Chi‐Sin Changchien, Jing‐Houng Wang, Chuan-Mo Lee, Sheng‐Nan Lu, Sheng‐Nan Lu and Cheng‐Yuan Peng and has published in prestigious journals such as PLoS ONE, Scientific Reports and The Journal of Infectious Diseases.

In The Last Decade

Chao‐Hung Hung

17 papers receiving 576 citations

Peers

Chao‐Hung Hung

EPIDE

HEPAT

SURGE

Montserrat Maldonado‐González Mexico

L. Raffaele Italy

S. Lobello Italy

Rikita Hatia United States

Mohamed Eltabbakh Egypt

Mohamed Mostafa Egypt

G Yamada Japan

Bita Behnava Iran

Pascal Veillon France

Aliu Akano Nigeria

Montserrat Maldonado‐González Mexico

Chao‐Hung Hung

332 ×0.6

EPIDE

305 ×0.6

HEPAT

34 ×1.1

10 ×0.5

SURGE

9 ×0.5

Citations per year, relative to Chao‐Hung Hung Chao‐Hung Hung (= 1×) peers Montserrat Maldonado‐González

Countries citing papers authored by Chao‐Hung Hung

Since Specialization

Citations

This map shows the geographic impact of Chao‐Hung Hung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chao‐Hung Hung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chao‐Hung Hung more than expected).

Fields of papers citing papers by Chao‐Hung Hung

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chao‐Hung Hung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chao‐Hung Hung. The network helps show where Chao‐Hung Hung may publish in the future.

Co-authorship network of co-authors of Chao‐Hung Hung

This figure shows the co-authorship network connecting the top 25 collaborators of Chao‐Hung Hung. A scholar is included among the top collaborators of Chao‐Hung Hung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chao‐Hung Hung. Chao‐Hung Hung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

Yen, Yi‐Hao, Sheng‐Nan Lu, Tsung‐Hui Hu, et al.. (2025). The association between antiviral therapy and 10-year overall survival of patients undergoing liver resection for hepatitis C virus- or hepatitis B virus-related hepatocellular carcinoma. Updates in Surgery.

Yu, Ming‐Lung, Pei‐Jer Chen, Chia‐Yen Dai, et al.. (2020). 2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. Journal of the Formosan Medical Association. 119(7). 1135–1157. 54 indexed citations

Wang, Hung‐Wei, Hsueh‐Chou Lai, Tsung‐Hui Hu, et al.. (2020). On-Treatment Changes in FIB-4 and 1-Year FIB-4 Values Help Identify Patients with Chronic Hepatitis B Receiving Entecavir Therapy Who Have the Lowest Risk of Hepatocellular Carcinoma. Cancers. 12(5). 1177–1177. 12 indexed citations

Chen, Chien‐Hung, Tsung‐Hui Hu, Jing‐Houng Wang, et al.. (2019). Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy. Hepatology International. 14(3). 317–325. 23 indexed citations

Huang, Chung‐Feng, Chao‐Hung Hung, Pin‐Nan Cheng, et al.. (2019). An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions. The Journal of Infectious Diseases. 220(4). 557–566. 13 indexed citations

Huang, Chun‐Chieh, Chao‐Hung Hung, Po‐Chin Liang, et al.. (2018). Multidisciplinary Taiwan Consensus Recommendations for the Use of DEBDOX-TACE in Hepatocellular Carcinoma Treatment. Liver Cancer. 7(4). 312–322. 13 indexed citations

Yen, Yi‐Hao, et al.. (2018). APRI and FIB-4 in the evaluation of liver fibrosis in chronic hepatitis C patients stratified by AST level. PLoS ONE. 13(6). e0199760–e0199760. 49 indexed citations

Yu, Ming‐Lung, Chao‐Hung Hung, Yi‐Hsiang Huang, et al.. (2018). Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions. Journal of the Formosan Medical Association. 118(2). 556–564. 7 indexed citations

Chen, Chien‐Hung, Chuan-Mo Lee, Hsueh‐Chou Lai, et al.. (2017). Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir. Oncotarget. 8(54). 92431–92441. 49 indexed citations

10.

Yen, Yi‐Hao, Jing‐Houng Wang, Sheng‐Nan Lu, et al.. (2016). MicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirin. Scientific Reports. 6(1). 33816–33816. 8 indexed citations

11.

Chen, Chien‐Hung, Chao‐Hung Hung, Tsung‐Hui Hu, et al.. (2015). Association Between Level of Hepatitis B Surface Antigen and Relapse After Entecavir Therapy for Chronic Hepatitis B Virus Infection. Clinical Gastroenterology and Hepatology. 13(11). 1984–1992.e1. 77 indexed citations

12.

Tseng, Po‐Lin, Jing‐Houng Wang, Hung‐Da Tung, et al.. (2010). Optimal treatment increased survival of hepatocellular carcinoma patients detected with community‐based screening. Journal of Gastroenterology and Hepatology. 25(8). 1426–1434. 32 indexed citations

13.

Wang, Jing‐Houng, Chao‐Hung Hung, Yi‐Hao Yen, et al.. (2009). Long-term efficacy of plasma-derived and recombinant hepatitis B vaccines in a rural township of Central Taiwan. Vaccine. 27(12). 1858–1862. 44 indexed citations

14.

Wang, Jing‐Houng, Chi‐Sin Changchien, Chao‐Hung Hung, et al.. (2009). Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: Longitudinal study using FibroScan. Journal of Gastroenterology and Hepatology. 25(5). 964–969. 67 indexed citations

15.

Wang, Jing‐Houng, et al.. (2008). Changing aetiology of liver dysfunction in the new generation of a hepatitis B and C‐endemic area: cross‐sectional studies on adolescents born in the first 10 years after universal hepatitis B vaccination. Liver International. 28(9). 1298–1304. 7 indexed citations

16.

Chen, Chien‐Hung, Chuan–Mo Lee, Chao‐Hung Hung, et al.. (2007). Clinical significance and evolution of core promoter and precore mutations in HBeAg‐positive patients with HBV genotype B and C: a longitudinal study. Liver International. 27(6). 806–815. 43 indexed citations

17.

Hung, Chao‐Hung, et al.. (2005). Antiviral therapy after non‐surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. Journal of Gastroenterology and Hepatology. 20(10). 1553–1559. 35 indexed citations

18.

Hung, Chao‐Hung, et al.. (2005). Combination therapy with interferon‐α and ribavirin in patients with dual hepatitis B and hepatitis C virus infection. Journal of Gastroenterology and Hepatology. 20(5). 727–732. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact